Gyre Therapeutics (GYRE) EBIAT: 2009-2025
Historic EBIAT for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $5.9 million.
- Gyre Therapeutics' EBIAT rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 114.12%. This contributed to the annual value of $17.9 million for FY2024, which is 120.94% up from last year.
- Per Gyre Therapeutics' latest filing, its EBIAT stood at $5.9 million for Q3 2025, which was up 276.65% from $1.6 million recorded in Q2 2025.
- Over the past 5 years, Gyre Therapeutics' EBIAT peaked at $51.6 million during Q2 2022, and registered a low of -$101.0 million during Q4 2023.
- In the last 3 years, Gyre Therapeutics' EBIAT had a median value of $3.8 million in 2023 and averaged -$5.1 million.
- As far as peak fluctuations go, Gyre Therapeutics' EBIAT tumbled by 453.61% in 2021, and later spiked by 359.09% in 2022.
- Over the past 5 years, Gyre Therapeutics' EBIAT (Quarterly) stood at -$20.3 million in 2021, then slumped by 37.23% to -$27.9 million in 2022, then crashed by 261.95% to -$101.0 million in 2023, then surged by 100.56% to $569,000 in 2024, then soared by 107.84% to $5.9 million in 2025.
- Its EBIAT was $5.9 million in Q3 2025, compared to $1.6 million in Q2 2025 and $3.7 million in Q1 2025.